Cost savings from anemia management with biosimilar epoetin alfa and increased access to targeted antineoplastic treatment: a simulation for the EU G5 countries. [electronic resource]
Producer: 20150420Description: 1599-609 p. digitalISSN:- 1744-8301
- Anemia -- chemically induced
- Antibodies, Monoclonal, Humanized -- economics
- Antibodies, Monoclonal, Murine-Derived -- economics
- Antineoplastic Agents -- adverse effects
- Bevacizumab
- Biosimilar Pharmaceuticals -- therapeutic use
- Drug Costs
- Epoetin Alfa
- Erythropoietin -- economics
- European Union
- Hematinics -- economics
- Humans
- Models, Economic
- Neoplasms -- drug therapy
- Recombinant Proteins -- economics
- Rituximab
- Trastuzumab
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.